Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017)
Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017)
复制标题
DOI：
10.1111/vco.12401
复制
发表时间：
2018-12-01
影响因子：
2.1
通讯作者：
Cohen, P. W.
中科院分区：
文献类型：
--
作者：
Moirano, S. J.;Dewey, C. W.;Cohen, P. W.
颅内神经胶质瘤是犬的常见恶性肿瘤，由于其侵袭性和缺乏临床有效治疗，预后不良。犬脑肿瘤的各种治疗方式的疗效以前已经描述过，虽然很少有数据存在的细胞毒性化疗的使用。进行了一项比较回顾性研究，包括2008年至2017年来自美国东北部5家兽医医院的40例病例。本研究中分析的与总生存期和预后意义相关的变量包括：年龄、性别、临床体征、临床体征持续时间、肿瘤位置和使用的治疗方案。与仅接受对症治疗的犬相比，接受洛莫司汀化疗的疑似颅内胶质瘤犬的生存时间（中位数，138天）更长（中位数，35天; P = 0.0026对数秩，0.0138 Wilcoxon）。此外，诊断前临床体征持续时间>= 16天（中位数，109天）与生存期较长相关。
Intracranial gliomas are a common malignancy in dogs, and are associated with a poor prognosis due to their aggressive nature and a lack of clinically effective treatments. The efficacies of various treatment modalities for canine brain tumours have been previously described, though little data exist on the use of cytotoxic chemotherapy. A comparative retrospective study, including 40 cases from 5 northeastern US veterinary hospitals, from 2008 to 2017, was conducted. Variables analysed in this study with relation to overall survival and prognostic significance included: age, sex, clinical signs, clinical sign duration, tumour location and treatment protocol used. Dogs with presumptive intracranial gliomas treated with lomustine chemotherapy lived longer (median, 138 days) than those treated exclusively with symptomatic care (median, 35 days; P = .0026 log-rank, 0.0138 Wilcoxon). Additionally, a duration of clinical signs >= 16 days prior to diagnosis (median, 109 days) was associated with a longer survival than a duration